Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms - Episode 5

Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

July 10, 2023

Rami Komrokji, MD, Andrew Brunner, MD, Hetty Carraway, MD, Yazan Madanat, MD, Amer Zeidan, MBBS, MHS

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Diagnosing Myelodysplastic Syndromes (MDS)

EP. 2: Risk Stratification of MDS

EP. 3: First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 4: Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

Now Viewing

EP. 5: Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

EP. 6: Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 7: Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

EP. 8: Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

EP. 9: Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

EP. 10: Treatment Approaches for Lower-Risk MDS With RAS Mutations

EP. 11: ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

EP. 12: Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

EP. 13: Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

EP. 14: Oral HMAs in Lower-Risk MDS Treatment

EP. 15: IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

EP. 16: Key Trials in the Treatment of Higher-Risk MDS

EP. 17: Final Thoughts on Recent Data Updates in MDS